ShortedShorted

COGSTATE LTD ORDINARY (CGS) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Cogstate (ASX:CGS): Healthcare Technology Momentum Keeps This Small-Cap in Focus

Highlights Cogstate continues attracting attention following strong earnings growth and a debt-free balance sheet. Digital cognitive assessment remains an expanding area within global healthcare and clinical research. Clinical trial activity and recurring customer demand continue shaping the company's long-term growth profile. Cogstate Ltd (ASX:CGS), an Australian healthcare technology company specialising in digital cognitive assessment, has attracted renewed...

Continue reading
Kalkine
Neutral
just now

Could CGS (ASX:CGS) Be the Penny Stock Turning Heads This Week?

Highlights Cogstate has attracted attention after delivering strong earnings momentum and securing fresh healthcare-related contracts. Verbrec and Smart Parking are among other profitable small-cap names drawing interest across the market. Strong earnings, healthy balance sheets and genuine commercial activity continue to separate quality penny stocks from speculative peers. Cogstate is leading attention among ASX penny stocks as profitability, earnings momentum and healthcare sector opportun...

Continue reading
Kalkine
Neutral
just now

Why Are Cogstate (ASX:CGS) and Smart Parking (ASX:SPZ) Leading ASX Penny Stocks?

Highlights Cogstate (ASX:CGS) draws attention for consistent earnings momentum and clinical data-driven business strength. Smart Parking (ASX:SPZ) stands out for scalable parking technology solutions and disciplined balance sheet approach. ASX penny stocks shift focus toward quality small caps within broader ASX 300 sentiment trends. ASX penny stocks are gaining renewed attention as investors shift toward quality small caps like Cogstate and Smart Parking, focusing on healthcare innovat...

Continue reading
Kalkine
Positive
just now

Bell Potter Backs Cogstate as Healthcare Tech Growth Gains Momentum

Highlights Cogstate continues expanding its presence in neuroscience-focused clinical trials. Growing demand from biopharma customers and strategic partnerships are supporting business momentum. New opportunities in sleep disorders and psychiatry are helping diversify revenue sources. Cogstate continues building momentum through healthcare technology innovation, strategic partnerships and expanding opportunities across clinical research markets. Cogstate (ASX:CGS) has attracted renewed market...

Continue reading